Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Brain dopamine dysfunction in attention deficit/hyperactivity disorder (ADHD) could explain why stimulant medications, which increase dopamine signaling, are therapeutically beneficial. However while the acute increases in dopamine induced by stimulant medications have been associated with symptom improvement in ADHD the chronic effects have not been investigated. METHOD: We used positron emission tomography and [(11)C]cocaine (dopamine transporter radioligand) to measure dopamine transporter availability in the brains of 18 never-medicated adult ADHD subjects prior to and after 12 months of treatment with methylphenidate and in 11 controls who were also scanned twice at 12 months interval but without stimulant medication. Dopamine transporter availability was quantified as non-displaceable binding potential using a kinetic model for reversible ligands. RESULTS: Twelve months of methylphenidate treatment increased striatal dopamine transporter availability in ADHD (caudate, putamen and ventral striatum: +24%, p<0.01); whereas there were no changes in control subjects retested at 12-month interval. Comparisons between controls and ADHD participants revealed no significant difference in dopamine transporter availability prior to treatment but showed higher dopamine transporter availability in ADHD participants than control after long-term treatment (caudate: p<0.007; putamen: p<0.005). CONCLUSION: Upregulation of dopamine transporter availability during long-term treatment with methylphenidate may decrease treatment efficacy and exacerbate symptoms while not under the effects of the medication. Our findings also suggest that the discrepancies in the literature regarding dopamine transporter availability in ADHD participants (some studies reporting increases, other no changes and other decreases) may reflect, in part, differences in treatment histories.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, almost all imaging studies on neurotransmitters have been performed in patients that received (chronic) pharmacotherapy, which may have influenced the scan directly, due to competition of the drug with a radioligand for a specific binding site, or indirectly because the brain adapts to the pharmacological effects (Wang et al., 2013).”
From Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders (2014) · cites this paper as Wang et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, almost all imaging studies on neurotransmitters have been performed in patients that received (chronic) pharmacotherapy, which may have influenced the scan directly, due to competition of the drug with a radioligand for a specific binding site, or indirectly because the brain adapts to the pharmacological effects (Wang et al., 2013).”
From Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders (2014) · cites this paper as Wang et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“research has shown that chronic MPH application is able to upregulate striatal dopamine turnover (Wang et al., 2013).”
From Differentiating neural reward responsiveness in autism versus ADHD (2014) · cites this paper as Wang et al., 2013
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In another study, in adults with ADHD, long-term MPH treatment increased striatal DAT availability (216).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Logan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479
Self-citationVolkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885
Self-citationEvaluating Dopamine Reward Pathway in ADHD: Clinical Implications
Volkow, N. D., Wang, G.-J., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F., Fowler, J. S., Zhu, W., Logan, J., Ma, Y., et al. (2009) · JAMA · doi:10.1001/jama.2009.1308 · Cited by 728 · cited 1×
“Full characteristics of the subjects have been described previously [5], so only a summary will be presented here.”
BackgroundSelf-citationdel Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685
(2012) · PubMed · Cited by 526
Self-citationVolkow, N. D., Wang, G.-J., Newcorn, J., Telang, F., Solanto, M. V., Fowler, J. S., Logan, J., Ma, Y., Schulz, K., Pradhan, K., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.8.932 · Cited by 331
Self-citationKuczenski, R., & Segal, D. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-16-07264.2002 · Cited by 316 · cited 1×
“Indeed, studies on the chronic effects of MPH have reported conflicting results with some documenting sensitization to the locomotor effects of MPH [21], others tolerance [22], and others no changes [23].”
BackgroundZahniser, N. R., & Doolen, S. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00158-9 · Cited by 310
Antidepressants in panic disorder: clinical and preclinical mechanisms.
Conners, C. K. (1998) · PubMed · Cited by 282
Altered responsiveness to cocaine in rats exposed to methylphenidate during development
Andersen, S. L., Arvanitogiannis, A., Pliakas, A. M., LeBlanc, C., & Carlezon, W. A. (2002) · Nature Neuroscience · doi:10.1038/nn777 · Cited by 259 · cited 1×
“Whereas one study reported that MPH pretreatment in preadolescence or in adulthood decreased the rewarding effects of cocaine (as assessed by conditioned place preference) later in life [24], two others [25,26] reported that chronic MPH treatment in adolescence or in adulthood enhanced cocaine’s reinforcing effects (a…”
Brandon, C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00281-0 · Cited by 259
Brain dopamine transporter levels in treatment and drug naive adults with ADHD
Volkow, N. D., Wang, G.-J., Newcorn, J., Fowler, J. S., Telang, F., Solanto, M. V., Logan, J., Wong, C., Ma, Y., Swanson, J. M., et al. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.10.014 · Cited by 249
Self-citationVolkow, N. D., Wang, G.-J., Tomasi, D., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F. W., Fowler, J. S., Logan, J., Wong, C. T., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4461-11.2012 · Cited by 237 · cited 1×
“However, while the acute DA enhancing effects of MPH have been associated with symptom improvement in children [3] and adults [4] with ADHD very little work has been done to evaluate its chronic effects in brain DA signaling.”
BackgroundSelf-citationMalison, R. T., Best, S. E., van Dyck, C. H., McCance, E. F., Wallace, E. A., Laruelle, M., Baldwin, R. M., Seibyl, J. P., Price, L. H., Kosten, T. R., et al. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.832 · Cited by 154
Swanson, J. M., Sandman, C. A., Deutsch, C., & Baren, M. (1983) · Pediatrics · doi:10.1542/peds.72.1.49 · Cited by 137
Self-citationRosa-Neto, P., Lou, H. C., Cumming, P., Pryds, O., Karrebaek, H., Lunding, J., & Gjedde, A. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2004.11.031 · Cited by 135
Gulley, J. M., & Zahniser, N. R. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.064 · Cited by 117
Striatal Dopaminergic Abnormalities in Human Cocaine Users
Little, K. Y., Zhang, L., Desmond, T., Frey, K. A., Dalack, G. W., & Cassin, B. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.238 · Cited by 116 · cited 1×
“Indeed humans, postmortem and imaging studies have shown increased DAT (20–50%) in the striatum of chronic cocaine abusers when compared with controls [17,18].”
BackgroundCrawford, C. A., McDougall, S. A., Meier, T. L., Collins, R. L., & Watson, J. B. (1998) · Psychopharmacology · doi:10.1007/s002130050536 · Cited by 85
Krause, J., la Fougere, C., Krause, K.-H., Ackenheil, M., & Dresel, S. H. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0602-x · Cited by 84
Psychopharmacology: concepts and opinions about the use of stimulant medications
Swanson, J. M., & Volkow, N. D. (2009) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2008.02062.x · Cited by 78 · cited 1×
“amphetamine), which enhance DA signaling have been used for decades as a first line treatment option [2].”
Self-citationPretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine
Schenk, S., & Izenwasser, S. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00735-9 · Cited by 76
McNamara, C., Davidson, E. S., & Schenk, S. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90532-x · Cited by 71
Koff, J. M., Shuster, L., & Miller, L. G. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38476-4 · Cited by 64
Methylphenidate hydrochloride given with or before breakfast
Swanson, J. M., Sandman, C. A., Deutsch, C., & Baren, M. (1983) · Journal of the American Academy of Child Psychiatry · doi:10.1097/00004583-198311000-00019 · Cited by 62
Self-citationPlasma input function determination for PET using a commercial laboratory robot
Alexoff, D. L., Shea, C. E., Fowler, J. S., King, P. T., Gatley, S. J., Schlyer, D. J., & Wolf, A. P. (1995) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(95)00042-v · Cited by 56
Self-citationSproson, E. J., Chantrey, J., Hollis, C., Marsden, C. A., & Fone, K. C. F. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500202 · Cited by 41
Research works printed but not linked: 2
- CK Conners, 1998, Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring, J Clin Psychiatry, 59 Suppl 7, 24
- ND Volkow, 2013, Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with ADHD, Journal of neuroscience
Cited by
Updated European Consensus Statement on diagnosis and treatment of adult ADHD
Kooij, J. J. S., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., Thome, J., Dom, G., Kasper, S., Nunes Filipe, C., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2018.11.001 · Cited by 686
Faraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631
“In another study, in adults with ADHD, long-term MPH treatment increased striatal DAT availability (Wang et al., 2013).”
Evaluation of neurofeedback in ADHD: The long and winding road
Arns, M., Heinrich, H., & Strehl, U. (2014) · Biological Psychology · doi:10.1016/j.biopsycho.2013.11.013 · Cited by 404
Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis
Van Doren, J., Arns, M., Heinrich, H., Vollebregt, M. A., Strehl, U., & K. Loo, S. (2019) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-018-1121-4 · Cited by 361
Blum, K., Oscar-Berman, M., Demetrovics, Z., Barh, D., & Gold, M. S. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8726-5 · Cited by 187
Metadata
- Authors
- Wang, G.-J., Volkow, N. D., Wigal, T., Kollins, S. H., Newcorn, J. H., Telang, F., Logan, J., Jayne, M., Wong, C. T., Han, H., Fowler, J. S., Zhu, W., & Swanson, J. M.
- Affiliations
- Brookhaven National Laboratory (US)
- National Institutes of Health (US)
- University of California, Irvine (US)
- Duke University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Stony Brook University (US)
- Corresponding author
- Wang, Gene-Jack
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-15
- Volume
- 8
- Issue
- 5
- Pages
- e63023
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3655054
- OpenAlex
- W2059137431
- Cited by
- 144
- References
- 29
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 9 · 2023: 11 · 2022: 13 · 2021: 15 · 2020: 8 · 2019: 8 · 2018: 14 · 2017: 15 · 2016: 10 · 2015: 8 · 2014: 15 · 2013: 5
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Energy (DE‐ACO2‐76CH00016, 76CH00016)
- Orexigen Therapeutics
- Stony Brook University
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (Z01AA000550)
- National Institute of Mental Health (R01MH066961)
- National Center for Research Resources (M01RR010710)
- Biological and Environmental Research
- Brookhaven National Laboratory (DE-ACO2-76CH00016)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- attention deficit hyperactivity disorder, dopamine transporter, methylphenidate, striatum, caudate nucleus, putamen, ventral striatum, treatment efficacy, adult ADHD
- MeSH terms
- Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Caudate Nucleus, Cocaine, Female, Humans, Male, Methylphenidate, Putamen, Case-Control Studies, Radiopharmaceuticals, Positron-Emission Tomography, Dopamine Plasma Membrane Transport Proteins, Young Adult, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.